....Like Witty, she argued that reliable cashflows from vaccines and consumer products are a natural counterweight to the higher risk and more volatile business of developing pharmaceutical drugs. And she agreed that there are benefits from being able to switch prescription
medicines to the consumer category when patents expire. ...
[Read full article on Guardian
Wednesday 26th of April 2017 06:37:04 PM